Ceftazidime + tazobactum injection

Product Details
img
Name Of Product(Genric Name) :

Ceftazidime + tazobactum injection

Dosage :

1GM+125MG

Product Description :

CEFTAZIDIME + TAZOBACTAM INJECTION
1 g + 125 mg

Sterile Powder for Solution for Intravenous Administration

  1. COMPOSITION

Each vial contains:

Ceftazidime Sodium equivalent to Ceftazidime ............... 1 g

Tazobactam Sodium equivalent to Tazobactam ............... 125 mg

Excipients: As applicable.

  1. PHARMACEUTICAL FORM

Sterile, white to off-white powder for solution for intravenous administration.

  1. THERAPEUTIC CLASS

Third-Generation Cephalosporin Antibiotic + β-Lactamase Inhibitor

  1. INDICATIONS

Ceftazidime + Tazobactam Injection is indicated for the treatment of serious bacterial infections caused by susceptible microorganisms.

It may be used in the treatment of:

• Lower respiratory tract infections
• Complicated urinary tract infections
• Intra-abdominal infections
• Skin and soft-tissue infections
• Bone and joint infections
• Septicemia and bloodstream infections
• Serious infections caused by susceptible Pseudomonas aeruginosa
• Other severe Gram-negative bacterial infections

Treatment should be guided by the susceptibility of the causative organism and applicable antimicrobial guidelines.

  1. CONTRAINDICATIONS

Ceftazidime + Tazobactam is contraindicated in patients with known hypersensitivity to ceftazidime, tazobactam, other cephalosporins, penicillins, or any component of the formulation.

  1. DRUG INTERACTIONS

Particular consideration may be required with concomitant use of:

• Aminoglycoside antibiotics
• Other nephrotoxic medicines
• Diuretics
• Other β-lactam antibiotics
• Anticoagulants such as warfarin

The treating physician should review all concomitant medications before administration.

  1. ADMINISTRATION

Ceftazidime + Tazobactam Injection is intended for intravenous administration.

The contents of the vial should be reconstituted with a suitable compatible diluent under appropriate aseptic conditions.

The reconstituted solution should be further diluted as required and administered by a qualified healthcare professional according to the approved product information and institutional protocol.

For Intravenous Use Only.

  1. STORAGE

Store according to the storage conditions stated on the approved product label.

Protect from excessive heat, moisture and light.

After reconstitution/dilution, use within the period specified in the approved product information.


Dry Powder Injection